The OHSU Research Cytogenetics Fee for Service Lab is exploring opportunities to expand its business model through new services. It currently offers a range of cytogenetics services on a fee-for-service basis but sees potential to better meet unfulfilled needs. The presentation recommends taking an agile approach to iteratively develop and test new business hypotheses over six-month cycles, starting with transgenic core testing. This would involve defining specifications, building prototypes, road testing with customers, and evaluating feedback to refine or pivot the concept. The goal is to validate market interest and map a path to a proven business model that leverages existing resources to generate additional revenue streams.
Here are some insights and case studies from 4 of the speakers who will be at QSP Congress. We asked them 4 questions and compiled them into one document. They give real personal opinions on some of the topics that are so far defining the adoption and application of systems pharmacology.
Pharma IQ brings you Clinical Trial Supply Europe Conference Profit. Successfully cutting costs and overages whilst increasing the flexibility and reactivity of your clinical supply network to support global clinical trials.
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
Here are some insights and case studies from 4 of the speakers who will be at QSP Congress. We asked them 4 questions and compiled them into one document. They give real personal opinions on some of the topics that are so far defining the adoption and application of systems pharmacology.
Pharma IQ brings you Clinical Trial Supply Europe Conference Profit. Successfully cutting costs and overages whilst increasing the flexibility and reactivity of your clinical supply network to support global clinical trials.
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
We describe what we have learned from four years of collaborating across the industry/not-for-profit boundary. Over this time we pursued multiple projects and some of the lessons learned are described here.
Many large pharma companies have reduced their research activity at the very early, hit- and lead- seeking phase of research. To compensate, organisations are becoming more porous and working more collaboratively in risk-sharing arrangements. Both parties need to give up some control, but gain a great deal in return
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
L'intervento di Rachele Berria (Global Vice President Primary Care Medical Unit Sanofi) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.
Need for an Integrated approach to Formulation Research and Knowledge ManagementAjaz Hussain
1. Confidence in Generics: Need for an Integrated
approach to Formulation Research and Knowledge
Management (Ajaz Hussain)
2. Mechanism for an integrated approach to Formulation
Research, Knowledge Management, & Knowledge
sharing with FDA & Industry (Steve Byrn)
3. Integrated approach for evolving standards for
formulation design - case example NTI's (Ken Morris)
4. Integrated approach for evolving standard for analytical
characterization - case example excipient variability
(Eric Munson)
Pharmaceutical quality decisions are made by multidisciplinary teams (a range of maturity), at different times and in various organizations; understanding of the QbD paradigm and methodology is derived experientially -One Quality Voice is hard to achieve!
Legacy challenges, various ontological assumptions, and weak epistemology curtails knowledge sharing, delays consensus and keeps us trapped in a reactive mode (3rd Order)
The risk of irrational decision making needs to be accounted. ”Cut-paste” or “check-the-box” practices are reminders that we are not achieving an optimal integration or practicing systems thinking.
A reactive approach (3rd Order) to filling the noted gaps poses risk of continued erosion in the confidence the public should have in our assurance of pharmaceutical quality
We need a thoughtful, planned approach to filling these gaps –NIPTE should take on this challenge! Will it?
Wearables are so 2015. Will insertable devices get under your skin?Kayla J Heffernan
10 minute talk at UX Australia 2016 held in Melbourne.
ABOUT THE TALK:
Over the last century the body has emerged as a platform for devices, including internal medical devices and wearable fitness monitors. Within the last decade individuals have begun voluntarily inserting non-medical devices into their bodies. What are people putting in their bodies and why? Are insertables the next thing?
ABOUT THE SPEAKER:
Kayla J Heffernan is a UX designer at SEEK who is also undertaking her PhD in interaction design at The University of Melbourne exploring a new category of device: insertables – devices that go in, through and underneath the skin.
Wearable Medical Records Talk at Wearables Tech Conferencedrchrono
Daniel Kivatinos, cofounder and COO of drchrono talks about Wearable Medical Records at the Wearable Tech Conference
http://www.wearablestechcon.com/
A video of this talk can be found here:
https://www.youtube.com/watch?v=87lGx5GJ7FY&feature=youtu.be
We describe what we have learned from four years of collaborating across the industry/not-for-profit boundary. Over this time we pursued multiple projects and some of the lessons learned are described here.
Many large pharma companies have reduced their research activity at the very early, hit- and lead- seeking phase of research. To compensate, organisations are becoming more porous and working more collaboratively in risk-sharing arrangements. Both parties need to give up some control, but gain a great deal in return
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
L'intervento di Rachele Berria (Global Vice President Primary Care Medical Unit Sanofi) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.
Need for an Integrated approach to Formulation Research and Knowledge ManagementAjaz Hussain
1. Confidence in Generics: Need for an Integrated
approach to Formulation Research and Knowledge
Management (Ajaz Hussain)
2. Mechanism for an integrated approach to Formulation
Research, Knowledge Management, & Knowledge
sharing with FDA & Industry (Steve Byrn)
3. Integrated approach for evolving standards for
formulation design - case example NTI's (Ken Morris)
4. Integrated approach for evolving standard for analytical
characterization - case example excipient variability
(Eric Munson)
Pharmaceutical quality decisions are made by multidisciplinary teams (a range of maturity), at different times and in various organizations; understanding of the QbD paradigm and methodology is derived experientially -One Quality Voice is hard to achieve!
Legacy challenges, various ontological assumptions, and weak epistemology curtails knowledge sharing, delays consensus and keeps us trapped in a reactive mode (3rd Order)
The risk of irrational decision making needs to be accounted. ”Cut-paste” or “check-the-box” practices are reminders that we are not achieving an optimal integration or practicing systems thinking.
A reactive approach (3rd Order) to filling the noted gaps poses risk of continued erosion in the confidence the public should have in our assurance of pharmaceutical quality
We need a thoughtful, planned approach to filling these gaps –NIPTE should take on this challenge! Will it?
Wearables are so 2015. Will insertable devices get under your skin?Kayla J Heffernan
10 minute talk at UX Australia 2016 held in Melbourne.
ABOUT THE TALK:
Over the last century the body has emerged as a platform for devices, including internal medical devices and wearable fitness monitors. Within the last decade individuals have begun voluntarily inserting non-medical devices into their bodies. What are people putting in their bodies and why? Are insertables the next thing?
ABOUT THE SPEAKER:
Kayla J Heffernan is a UX designer at SEEK who is also undertaking her PhD in interaction design at The University of Melbourne exploring a new category of device: insertables – devices that go in, through and underneath the skin.
Wearable Medical Records Talk at Wearables Tech Conferencedrchrono
Daniel Kivatinos, cofounder and COO of drchrono talks about Wearable Medical Records at the Wearable Tech Conference
http://www.wearablestechcon.com/
A video of this talk can be found here:
https://www.youtube.com/watch?v=87lGx5GJ7FY&feature=youtu.be
A small presentation on Wearable Devices in HealthCare. It emphasise the need of FDA Regulatory route and Reimbursement Pathway to break the confinement of Wearable Devices to a very small part of the Population.
What if there is no killer app for wearables?Valencell, Inc
There are likely to be hundreds use cases for wearables across many different industries and markets that wearables will enable. The form factors, data, and user interfaces will likely be very different, but the key is to understand that the wearable devices are one part of a comprehensive user experience that supports achieving specific goals or objectives. Even the most common current use case - fitness and activity tracking - is being vastly underserved by the offerings in the market today because they lack a compelling user experience. And it’s critical we get those objectives and user experiences right if the wearables market is going to realize the massive growth that many are predicting in the next few years.
These slides use concepts from my (Jeff Funk) course entitled analyzing hi-tech opportunities to analyze the increasing economic feasibility of wearable electronics in health care applications. Rapid improvements in sensors, integrated circuits, transceivers, displays, mobile phones, and wireless networks are causing the cost to fall and the performance to rise for wearable applications. These slides analyze hand, head, and body worn electronics in detail including smart watches, wrist and finger devices, smart glasses and textiles, patches, and foot and arm wear. They also analyze a wide variety of sensors for collecting healthcare information including inertial, bio, chemical, and haptic sensors.
Sensors for Wearable Electronics & Mobile Healthcare 2015 Report by Yole Deve...Yole Developpement
Yole;report;market;technology;application;research;trend;player;analysis;free;data
MEMS, Compound Semiconductors, LED, Image Sensors, Optoelectronics, Microfluidics & Medical, Photovoltaics, Advanced Packaging, Power Electronics
More information on that report at http://www.i-micronews.com/reports.html
David cocker feasibility_and_web_miningDavid Cocker
Feasibility studies aim to objectively and rationally uncover the strengths and weaknesses of existing resources required to carry through, and ultimately predict the prospects for success
Can software do the hard work for you.
10th Anniversary Compound Libraries
VISIT THE CONFERENCE WEBSITE HERE: http://bit.ly/CompoundLibrariesSlideshare
Maximizing information in early-phase R&D for an optimal library design and target selection
We are excited to conduct the 10th annual meeting of the formerly known Compound Libraries conference! Over the last decade we have provided the pharmaceutical R&D community with a wonderful platform for exchanging knowledge and ideas about how best to optimize the qualification of drug candidates.
We have hosted almost all major pharmaceutical companies and heard dozens of case-studies relating to important and acute issues. When returning back to the programs from previous years, it is interesting to look at the timeline of changing approaches, trends and market-related developments. Our topical spectrum ranged from compound management and acquisition to collaboration frameworks, open access, library design, screening and analysis.
This year we bring you 15 case studies about the most burning issues in early-stage discovery today and offer you a valuable trend-analysis and networking with peers and colleagues from pharmaceutical companies, biotechs, CROs and academic research institutes.
Benefit from participating in discussions about the following topics:
- 10 years perspective on synthesizing and designing compound libraries
- What is the role of ligand efficiency metrics in drug discovery? Have your say in this controversial debate!
- Next generation library design - working towards better PPI and epigenetic libraries
- Exploration of bioactive and novel chemical space by application of privileged structure concept design
- Learn from Janssen’s experience with the assembly of the IMI European Lead Factory (ELF) library
- What is the real potential of macrocycles and are they the drugs of the future?
10th International Conference Compound Libraries 2014Torben Haagh
VISIT THE CONFERENCE WEBSITE HERE:
http://bit.ly/CompoundLibrariesSlideshare
Maximizing information in early-phase R&D for an optimal library design and target selection
We are excited to conduct the 10th annual meeting of the formerly known Compound Libraries conference! Over the last decade we have provided the pharmaceutical R&D community with a wonderful platform for exchanging knowledge and ideas about how best to optimize the qualification of drug candidates.
We have hosted almost all major pharmaceutical companies and heard dozens of case-studies relating to important and acute issues. When returning back to the programs from previous years, it is interesting to look at the timeline of changing approaches, trends and market-related developments. Our topical spectrum ranged from compound management and acquisition to collaboration frameworks, open access, library design, screening and analysis.
This year we bring you 15 case studies about the most burning issues in early-stage discovery today and offer you a valuable trend-analysis and networking with peers and colleagues from pharmaceutical companies, biotechs, CROs and academic research institutes.
Don’t miss our 10th anniversary and join us in Berlin to take part at our legacy conference!
Benefit from participating in discussions about the following topics:
-10 years perspective on synthesizing and designing compound libraries
-What is the role of ligand efficiency metrics in drug discovery? Have your say in this controversial debate!
-Next generation library design - working towards better PPI and epigenetic libraries
-Exploration of bioactive and novel chemical space by application of privileged structure concept design
-Learn from Janssen’s experience with the assembly of the IMI European Lead Factory (ELF) library
-What is the real potential of macrocycles and are they the drugs of the future?
Strand SmartLab - Enabling Precision Medicine at community HospitalsHarsha Rajasimha
Strand SmartLab is a complete soup to nuts solution that enables a community hospital to establish precision medicine testing services in-house. This enables the retention of revenues internally rather than loosing them to external third party laboratories. Genomics driven precision medicine for Cancer and other diseases require highly skilled people, lab equipment, processes, regulatory experts, bigdata software, databases and curation, medical geneticists to interpret the results in clinical settings and genetic counselors. Strand SmartLab brings all these to your institution in a pre-packaged solution.
Science Exchange - Measuring Research Efficiency & QualityScience Exchange
Presentation by Science Exchange Founder & CEO Elizabeth Iorns, Ph.D. at the Altmetrics 2012 Workshop covering the company's plan to address problems with the efficiency and quality of scientific research.
How Researchers Can Get Science Done Faster Using an R&D Services MarketplaceSC CTSI at USC and CHLA
Date: Feb 6, 2019
Topic: How Researchers Can Get Science Done Faster Using an R&D Services Marketplace
Speaker: Dr. Zev Wisotsky is a Senior Scientist and R&D Specialist at Science Exchange, where he assists researchers in connecting with the right R&D providers for their experiments and alerts his clients to newly available technologies. Dr. Wisotsky earned his PhD in neuroscience investigating taste detection using fruit fly and mosquito models at UC Riverside. He then completed postdoctoral research at Stanford studying the role of brain regions involved in fear memory and addiction through optogenetic silencing of different brain circuits.
Overview: Science Exchange is an open marketplace for scientific research that breaks down barriers to collaboration and innovation. The platform makes it easy for researchers to access more than 6,000 services from a network of over 2,500 qualified research providers. In this webinar, you will learn how researchers can use Science Exchange to access new technologies, get competitive quotes for specific projects, and order from any service provider under a single, pre-established contract. The presentation will also include examples of successful projects and collaborations, initiated on the Science Exchange platform, that have accelerated breakthrough
Blueprints to blue sky – analyzing the challenges and solutions for IHC compa...Candy Smellie
Manual assessment of biomarker expression is associated with significant inter- and intra reader variability. In some cases there are also limitations when it comes to sensitivity and specificity of manual biomarker assessment.
In one example to the left, the “pure” contribution of inter-reader variability associated with Ki67 assessment was quantified across 20 tumors and 126 participating labs. In that study, it was demonstrated how image analysis can be used to significantly reduce inter-reader variability.
In a another study, the National Danish Validation study of Her2, it was demonstrated how improved sensitivity/specificity of quantitative HER2 protein expression wrt gene amplification lead to significant cost savings in reflex testing.
By automating aspects of stain quality control, it will become scalable to he point where EQA organizations may be able and willing to offer more frequent – perhaps even on-demand – proficiency testing and calibration services.
It is possible that objective and quantitative standards will contribute to improve compliance with protocol recommendations.
In clinical multi-center trials it will be easier to standardize and monitor data from each center.
And it is our hope tha larger diagnostic pathology labs will be able to benefit from such a method by closely monitoring drift in staining quality for biomarkers.
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
Similar to Research Cytogenetic Lab Presentation (20)
Big data, RWE and AI in Clinical Trials made simple
Research Cytogenetic Lab Presentation
1. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
2. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Opportunities to Leverage Knowledge
and Expand the Business Model
3. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Opportunities
Market: Is there an unfulfilled or unanswered need?
Challenges: What is the right business model?
Nimble: How to continuously respond to the market
Manage Strategies to address uncertainty
4. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Opportunities
Seeking: Identifying a viable business model
Testing: Experimenting and hypothesizing
Listening: Internalizing the needs of customers
Refining: Iteratively responding and modifying
5. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Opportunities
Current State: Fee for service lab is about ten years old
A range of services are currently offered
Marketing has been by word-of-mouth
Sense there is an unfulfilled need
Competition: University of Wisconsin WiCell lab
Relationships: OHSU researchers
Knight Diagnostic Lab
Potential: Cancer research institutions
Pharmaceutical trials
Cell repositories
6. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Key principles: Craft a business model canvas
Develop an untested hypothesis
Define the requirements and resources
Prototype a minimum viable product
Road test by “getting out of the building”
Evaluate and refine the prototype
Repeat or pivot
Agile Development
7. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategize
Analyze
ImplementRoad Test
Evaluate
Agile Development
Revisit/ Refine
Pivot
8. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Business Model Canvas
Efficiency Value
Key Partnerships
Researchers
Cancer institutes
Institutional owners of
transgenic cores
Pharmaceutical companies
Key Activities
Karyotype chromosome analysis:
mouse/ human/ dog
Cell line verification via
karyotyping
Designer FISH probes
Reading cell samples & paraffin
tissue
Transgenic core testing to
improve clone outcomes
Breakage test to determine
genome instability
Value Proposition
Data and outcomes prove the
efficacy of services
Cost/ benefit of transgenic core
cell line verification/ business
case in time and cost
Web list of past and present
customers
Customized cell line testing
Parental cell line testing for
institutions
Rapid transgenic mouse studies
(24 – 48 hours)
Relationships
Knight Labs: self-labeled FISH
probes
Dr. Pejovic: chromosome
breakage studies
Dr. Drucker: confirmation FISH
Dr. Borzy: clinical trial support
Dr. Keller: karyotype
chromosome analysis
Customer Segments
Knight Labs
OHSU researchers
Dr. Chen, Harvard
Dr. McMann, USC
Pharmaceutical companies
clinical trials
Cell repositories: Coriell, ATCC
Key Resources
Confirmation of micro arrays
via custom FISH probes
Channels
How do we reach our
customers?
Cost Structure
$200/clone
8 to 10 samples per month
Are we charging enough??
Revenue Streams
Current price list is based on costs
Sliding scale based on funding source?
Can there be revenue sharing with the clinical lab?
Can custom FISH probes be licensed? Are they IP?
Competitors: WiCell University of Wisconsin
9. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Business Model Canvas
Efficiency Value
Key Partnerships
Researchers
Cancer institutes
Institutional owners of
transgenic cores
Pharmaceutical companies
Key Activities
Karyotype chromosome analysis:
mouse/ human/ dog
Cell line verification via
karyotyping
Designer FISH probes
Reading cell samples & paraffin
tissue
Transgenic core testing to
improve clone outcomes
Breakage test to determine
genome instability
Value Proposition
Data and outcomes prove the
efficacy of services
Cost/ benefit of transgenic core
cell line verification/ business
case in time and cost
Web list of past and present
customers
Customized cell line testing
Parental cell line testing for
institutions
Rapid transgenic mouse studies
(24 – 48 hours)
Relationships
Knight Labs: self-labeled FISH
probes
Dr. Pejovic: chromosome
breakage studies
Dr. Drucker: confirmation FISH
Dr. Borzy: clinical trial support
Dr. Keller: karyotype
chromosome analysis
Customer Segments
Knight Labs
OHSU researchers
Dr. Chen, Harvard
Dr. McMann, USC
Pharmaceutical companies
clinical trials
Cell repositories: Coriell, ATCC
Key Resources
Confirmation of micro arrays
via custom FISH probes
Channels
How do we reach our
customers?
Cost Structure
$200/clone
8 to 10 samples per month
Are we charging enough??
Revenue Streams
Current price list is based on costs
Sliding scale based on funding source?
Can there be revenue sharing with the clinical lab?
Can custom FISH probes be licensed? Are they IP?
Competitors: WiCell University of Wisconsin
Resource Driven
Innovations originating from existing infrastructure to expand or transform the business model
10. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategy
First Iteration Cycle – Six Month Plan
Develop a Hypothesis Analyze Implement Road Test Evaluate
“We can sell
transgenic core
testing to academic
research institutions.”
Define technical
specifications and
requirements
Identify key resources
and partnerships ISH
probes
Build prototype
(First round may be
virtual prototype)
Road test MVP with
select customer
segments
Document feedback,
efficacy, cost and
revenue
ç Revisit and Refine or Pivot to New Hypothesis ç
Recommendation
Leverage agile development tools to create a fee-for-service lab start-up
Begin with a focus on transgenic core testing
Manage the staff time and resource investment
Embrace a nimble mindset and be ready to pivot
11. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategy
First Iteration Cycle – Six Month Plan
Develop a Hypothesis Analyze Implement Road Test Evaluate
“We can sell
transgenic core
testing to academic
research institutions.”
Define technical
specifications and
requirements
Identify key resources
and partnerships ISH
probes
Build prototype
(First round may be
virtual prototype)
Road test MVP with
select customer
segments
Document feedback,
efficacy, cost and
revenue
ç Revisit and Refine or Pivot to New Hypothesis ç
Develop a Hypothesis
Frame the project objectives
Appropriate people/ right knowledge
Provide the appropriate resources
12. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategy
First Iteration Cycle – Six Month Plan
Develop a Hypothesis Analyze Implement Road Test Evaluate
“We can sell
transgenic core
testing to academic
research institutions.”
Define technical
specifications and
requirements
Identify key resources
and partnerships ISH
probes
Build prototype
(First round may be
virtual prototype)
Road test MVP with
select customer
segments
Document feedback,
efficacy, cost and
revenue
ç Revisit and Refine or Pivot to New Hypothesis ç
Analyze
Co-create with others across the organization
Look beyond the status quo
Explore multiple possibilities
13. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategy
First Iteration Cycle – Six Month Plan
Develop a Hypothesis Analyze Implement Road Test Evaluate
“We can sell
transgenic core
testing to academic
research institutions.”
Define technical
specifications and
requirements
Identify key resources
and partnerships ISH
probes
Build prototype
(First round may be
virtual prototype)
Road test MVP with
select customer
segments
Document feedback,
efficacy, cost and
revenue
ç Revisit and Refine or Pivot to New Hypothesis ç
Implement
Proof of concept via data and testimony
Demonstrate technique and speed
Create a tangible Minimum Viable Product (MVP)
14. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategy
First Iteration Cycle – Six Month Plan
Develop a Hypothesis Analyze Implement Road Test Evaluate
“We can sell
transgenic core
testing to academic
research institutions.”
Define technical
specifications and
requirements
Identify key resources
and partnerships ISH
probes
Build prototype
(First round may be
virtual prototype)
Road test MVP with
select customer
segments
Document feedback,
efficacy, cost and
revenue
ç Revisit and Refine or Pivot to New Hypothesis ç
Road Test
Target a range of customers
Spend sufficient time with each one
Strong communication tools
15. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategy
First Iteration Cycle – Six Month Plan
Develop a Hypothesis Analyze Implement Road Test Evaluate
“We can sell
transgenic core
testing to academic
research institutions.”
Define technical
specifications and
requirements
Identify key resources
and partnerships ISH
probes
Build prototype
(First round may be
virtual prototype)
Road test MVP with
select customer
segments
Document feedback,
efficacy, cost and
revenue
ç Revisit and Refine or Pivot to New Hypothesis ç
Evaluate
Continually re-assess
Re-visit the hypothesis
Manage synergies
16. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Strategy
First Iteration Cycle – Six Month Plan
Develop a Hypothesis Analyze Implement Road Test Evaluate
“We can sell
transgenic core
testing to academic
research institutions.”
Define technical
specifications and
requirements
Identify key resources
and partnerships ISH
probes
Build prototype
(First round may be
virtual prototype)
Road test MVP with
select customer
segments
Document feedback,
efficacy, cost and
revenue
ç Revisit and Refine or Pivot to New Hypothesis ç
Six Month Outcomes
Validate there is a market for transgenic core testing or pivot to a new hypothesis
Sample customers regarding their interest and price expectations
Understand the resources needed to build a start-up
Map a path toward a proven business model
17. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Execution
Timeline: Start with a six month plan
Deploy an agile development technique
Track milestones and manage progress
Resources: Committed start-up team
Prototype development lab time
MVP value proposition
Travel and marketing budgets
Needs include: Strong customer relationships
A robust marketing strategy
Diversified revenue streams
A clearly defined cost structure
18. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
Opportunities to Leverage Knowledge
and Expand the Business Model
19. MGMT 545 :: Goodfriend
OHSU Research Cytogenetics Fee for Service Lab
The following materials were referenced for this
presentation:
:: “Business Model Generation” Osterwalder & Pigneur, 2010
:: “Why the Lean Start-up Changes Everything” Blank, HBR, 2013
:: www.businessmodelhub.com
:: www.wicell.org
References